11 Results
Sort By:
Published on December 26, 2023
Bristol Myers Squibb (BMS) announced on Friday it will pay $14 billion in cash to acquire Karuna Therapeutics, a developer of therapeutics targeting psychiatric and neurological conditions. Karuna’s lead candidate KarXT (xanomeline-trospium) is a potential first-in-class drug that has demonstrated differentiated safety and efficacy in adult schizophrenia with additional indications…
Published on December 19, 2023
Digital biomarker company Altoida which is focused on using augmented reality and machine learning to identify neurological conditions, said that new research from the RADAR-AD consortium shows the promise of using augmented reality (AR)-based cognitive assessment for early identification and assessment of people with Alzheimer’s disease (AD). The findings, published…
Published on July 17, 2023
CRISPR-based therapies for Alzheimer’s are starting to emerge. At least two possible candidates were reported this week at the Alzheimer’s Association International Conference (AAIC) 2023. One aims to reduce the impact of APOE-e4, the strongest known Alzheimer’s risk gene. The other affects the brain’s production of beta amyloid, which is…
Published on May 11, 2023
Researchers have revealed the structure of an amyloid beta protein implicated in the progression of Alzheimer’s disease and provided a window into how the recently approved drug lecanemab works. The team found abundant small diffusible aggregates of amyloid beta protein in aqueous extracts from the brains of people with Alzheimer’s…
Published on May 11, 2023
Researchers at the Mayo Clinic have discovered a connection between sleep apnea and brain biomarkers that have been linked to an increased risk of stroke, Alzheimer’s disease, and cognitive decline. As many as 18 million Americans suffer from a lack of deep sleep caused by interruptions in their breathing pattern…
Published on April 20, 2023
Researchers at the Albert Einstein College of Medicine, NY have developed a simple memory test that may predict the risk of developing cognitive impairment related to diseases such as Alzheimer’s years before symptoms appear. Early cognitive decline tends to appear in the form of memory loss and difficulty concentrating. Dementia…
Published on January 20, 2023
Life Molecular Imaging announced it has commenced a Phase III clinical trial of PI-2620, a tau PET (positron emission tomography) imaging agent as a diagnostics for Alzheimer’s disease (AD). The open-label, multi-center, non-randomized trial, called ADvance, will assess the safety and efficacy of PI-2620 for the detection of tau deposition…
Published on December 8, 2022
Researchers at Tufts University in Boston have discovered that patients suffering from cognitive decline with higher levels of vitamin D in their brain have better cognitive function compared to patients with lower levels of the compound. Dementia affects nearly six million people in the U.S. alone and the numbers are…
Published on October 14, 2022
Researchers at St. Jude Children’s Research Hospital in Memphis, TN have developed a new model for Alzheimer’s disease demonstrating how defects in the RNA splicing machinery of the cell contribute to the condition. Alzheimer’s disease affects nearly six million people in the U.S. alone. Despite its prevalence, treatments to stop…
Published on October 4, 2022
A new study by researchers from Case Western Reserve University may help explain the sex-based difference in the incidence rate of Alzheimer’s disease (AD) that makes women more vulnerable to the disease. The research, published today in the journal Cell, shows that higher expression of the X-linked enzyme ubiquitin-specific peptidase…
Published on July 15, 2022
New research into Alzheimer’s disease (AD) treatment by a team led by Claudio Soto, PhD, professor in the Department of Neurology with McGovern Medical School at UTHealth Houston has shown in a mouse study that a whole exchange of blood decreased the formation in the brain of amyloid plaque. The…